Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability

Journal of Receptor, Ligand and Channel Research

Volumn 4, Issue , 2011, Pages 49-55

  Juruena, Mario F ^a   de Sena, Eduardo Pondé ^b   de Oliveira, Irismar Reis ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Adverse events; Amisulpride; Antipsychotic agents; Pharmacology

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; AKATHISIA; BODY MASS; BRADYCARDIA; DELUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOTENSION; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL INTERACTION; TORSADE DES POINTES; WEIGHT GAIN; XEROSTOMIA;

EID: 84864316387     PISSN: None     EISSN: 1178699X     Source Type: Journal    
DOI: 10.2147/jrlcr.s6239     Document Type: Review

References (50)

1. de Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J Clin Pharm Ther. 2006;31:523-534.
2. Kerwin RW. The new atypical antipsychotics. A lack of extra pyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994;164:141-148.
3. Kane JM. Clozapine in the treatment of schizophrenia. Encephale. 1996;22:7-11.
4. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004;4:53-7.
5. Siegfried SL, Fleischhacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management. London, UK: Martin Dunitz; 2001:59-94.
6. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. The J Pharmacol Exp Ther. 1994;271:1058-1066.
7. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004;4:53-57.
8. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 1994;271:1058-1066.
9. de Oliveira IR, Ribeiro MG, Fregoneze JB, de Sena EP, de Castro E, Silva E. Regional c-fos expression in rat brain may predict antipsychotic therapeutic window. J Clin Psychopharmacol. 2000;20: 705-706.
10. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
11. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160:13-23.
12. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997; 280:83-97.
13. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: A meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-190.
14. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 2003;6:553-564.
15. de Oliveira IR, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther. 1996;21: 349-358.
16. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106-115.
17. Lecrubier Y. Amisulpride: Progress and outcomes. Curr Med Res Opin. 2002;18 Suppl 3:18-22.
18. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: Relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205:119-128.
19. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
20. Buis W. Patient's opinions concerning side effects of neuroleptics. Am J Psychiatry. 1992;149:844-845.
21. Casey D. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57:40-45.
22. Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.
23. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl). 1998;137:223-232.
24. Kvachnina E, Liu G, Dityatev A, et al. 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci. 2005;25:7821-7830.
25. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158:360-369.
26. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): A review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14: 209-218.
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1203.
28. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
29. Carrière P, Bonhomme D, Lemperière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia. Eur Psychiatry. 2000;15:321-329.
30. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2010. [Epub ahead of print].
31. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62 Suppl 7:32-37.
32. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22-31.
33. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54:565-567.
34. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145-160.
35. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
36. de Hert MA, van WR, van ED, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
37. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
38. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68:1834-1839.
39. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999;88:107-117.
40. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs risperidone in chronic schizophrenia: Results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27:1071-1081.
41. Martin S, Ljo H, Peuskens J, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two months. Curr Med Res Opin. 2002;18:355-362.
42. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19: 63-69.
43. Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an atypical antipsychotic associated with low weight gain. Psychopharmacology (Berl). 2004;173:112-115.
44. Tandon R, Belmaker RH, Gattaz WF; Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008:100;20-38.
45. Motlová L. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Ann Clin Psychiatry. 2007;19:133-143.
46. American Psychiatric Association, 2008. Practice guidelines for the treatment of patients with schizophrenia. Available at: http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_6.aspx. Accessed July 25, 2011.
47. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005:19 Suppl 1:1-93.
48. Lin CC, Bai YM, Wang YC, et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J Clin Psychopharmacol. 2009;29:529-536.
49. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21:369-72
50. Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205-211.